By checking expression of CD44 and CD163 in glioma samples through IF, CD44+CD163+ cells were uncovered (Supplementary Figure 8), which confirmed that the CD44+ TAMs are in M2 phenotype. This evidence concerns the gene CD163 and central nervous system cancer.